Riskpilot← Back to searchSign inGet full accessIVRS AB
ABActiveOrg 5592075633Medicon VillageResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20192 employees
Revenue 2025
SEK 1,6M
+20% vs 2024
EBITDA margin
37.4%
-40% vs 2024
Equity ratio
53.3%
Financial strength
Net profit 2025
SEK 403K
-35% vs 2024
| Revenue | SEK 1,6M | +20% |
| EBITDA | SEK 614K | -40% |
| Net profit | SEK 403K | -35% |
| Total assets | SEK 2,6M | +10% |
| Equity | SEK 1,4M | +16% |
| Employees | 2 | — |
Legal name
IVRS AB
Org number
5592075633
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29 maj 2019
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska erbjuda konsulttjänster i form av framförallt forskning till företrädesvis kunder inom life science, samt direkt eller indirekt äga och förvalta aktier, värdepapper och fastigheter och annan fast och lös egendom och därmed förenlig verksamhet.
Address
Medicon Village
Email
ramin.massoumi@ivrs.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 637 | 2 490 | 2 265 | 1 367 | 1 643 |
| Staff expenses | — | −1 236 | −1 333 | −1 187 | −1 017 |
| EBITDA | 525 | 948 | 427 | 1 026 | 614 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 525 | 948 | 427 | 1 026 | 614 |
| Net financials | −4 | −0 | 7 | 48 | 47 |
| Profit before tax | 386 | 708 | 322 | 796 | 516 |
| Tax | −83 | −149 | −70 | −172 | −113 |
| Net profit | 303 | 559 | 252 | 623 | 403 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 106 | 1 921 | 1 657 | 2 380 | 2 609 |
| Equity | 358 | 727 | 789 | 1 197 | 1 391 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 459 | 665 | 226 | 263 | 154 |
| Total debt | 459 | 665 | 226 | 263 | 154 |
EBITDA margin
37.4%
This company
15.8%
Market median
+137% vs market
20212025
Equity ratio
53.3%
This company
38.2%
Market median
+40% vs market
20212025
Return on equity
29.0%
This company
18.4%
Market median
+58% vs market
20212025
Net profit margin
24.5%
This company
8.1%
Market median
+202% vs market
20212025
Asset turnover
0.63×
This company
1.12×
Market median
-44% vs market
20212025
Debt / equity
0.88×
This company
0.62×
Market median
+42% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of IVRS AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ramin Masoumi | Chief Executive Officer | 0 companies |
| Katarzyna Chmielarska Masoumi | Deputy Board Member | 0 companies |
| Karl Sebastian Hansson | Deputy Board Member | 0 companies |